Mabpharm Limited (2181.HK)

0.395 -0.005 (-1.25%) At close: 02:08PM HKT

Mabpharm Limited

Block G79
Lujia Road East Koutai Road West China Medical City
Taizhou 225300
China

https://www.mabpharm.cn

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 347

Key Executives

Name	Title	Pay	Exercised	Year Born
Dr. Hao Wang	Chief Scientist, CEO & Executive Director	1.21M	N/A	1969
Mr. Yunfeng Li	CFO, Joint Company Secretary & Executive Director	1.08M	N/A	1978
Mr. Jing Tao	VP & Executive Director	1.03M	N/A	1973
Dr. Sheng Hou	VP & Executive Director	75.56k	N/A	1978
Dr. Jing Li	Vice President	878.66k	N/A	1967
Mr. Ho Yin Tsang B.Com., L.L.B., L.L.M.	Joint Company Secretary	N/A	N/A	1986

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in HKD.

Description

Mabpharm Limited, a biopharmaceutical company, engages in research, development, and production of drugs and biosimilar drugs for cancers and autoimmune diseases in the People's Republic of China. The company's products under the Phase III clinical trial include CMAB007, a recombinant humanized anti-immunoglobulin E monoclonal antibody for treatment of asthma patients; CMAB009, a recombinant anti-EGFR chimeric monoclonal antibody for the first-line treatment of metastatic colorectal cancer; CMAB008, a recombinant anti-TNF-alpha chimeric monoclonal antibody for indications of rheumatoid arthritis, Crohn's disease, etc; and CMAB807 for osteoporosis indications. It is also developing CMAB819 that is in Phase I clinical trial for the treatment of metastatic non-small cell lung cancer, hepatocellular carcinoma, and head and neck squamous cell carcinomas; CMAB807X for the treatment of tumor bone metastasis; and CMAB015, a biosimilar candidate for secukinumab to treat psoriasis and ankylosing spondylitis. In addition, the company's products under the pre-clinical stage include CMAB017 for the treatment of advanced solid tumors; CMAB018, a biosimilar candidate for mepolizumab, for the treatment of asthma and eosinophilic granulomatous polyangiitis; CMAB022 for the treatment of inflammatory diseases; and CMAB023, a biosimilar drug candidate for Tezepelumab. Further, it is involved in research and development, manufacturing, technical consulting, technology transfer, and technical services of biological products, diagnostic reagents, chemical biological reagents, and drugs. The company was incorporated in 2018 and is headquartered in Taizhou, China.

Corporate Governance

Mabpharm Limited’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.